CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
0.00 (0.00%)
Real-time:   11:18AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.16 - 1.19
52 week 1.07 - 2.94
Open 1.17
Vol / Avg. 456,843.00/1.55M
Mkt cap 273.43M
P/E     -
Div/yield     -
EPS -0.81
Shares 231.72M
Beta 1.07
Inst. own 25%
Dec 2, 2015
CTi Biopharma Corp at Piper Jaffray Healthcare Conference - 12:00PM EST - Add to calendar
Nov 5, 2015
Q3 2015 CTi Biopharma Corp Earnings Call - Webcast
Nov 5, 2015
Q3 2015 CTi Biopharma Corp Earnings Release
Sep 29, 2015
CTi Biopharma Corp at Ladenburg Thalmann Life Sciences Conference
Sep 23, 2015
CTi Biopharma Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -3433.20% -156.85%
Operating margin -3314.63% -143.54%
EBITD margin - -105.32%
Return on average assets -194.37% -101.32%
Return on average equity - -220.85%
Employees 125 -
CDP Score - -


3101 Western Ave Ste 600
SEATTLE, WA 98121-3047
United States - Map
+1-206-2827100 (Phone)
+1-206-2846206 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 72
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 43
Bio & Compensation  - Reuters
Bruce J. Seeley Executive Vice President and Chief Commercial Officer
Age: 51
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 48
Bio & Compensation  - Reuters
Richard L. Love Independent Director
Age: 71
Bio & Compensation  - Reuters
Mary O'Neil Mundinger Independent Director
Age: 77
Bio & Compensation  - Reuters